CANF
Price
$4.29
Change
-$0.00 (-0.00%)
Updated
Jan 15, 11:16 AM (EDT)
Capitalization
3.67M
Intraday BUY SELL Signals
CUE
Price
$0.30
Change
-$0.04 (-11.76%)
Updated
Jan 15, 11:20 AM (EDT)
Capitalization
31.11M
68 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CANF vs CUE

Header iconCANF vs CUE Comparison
Open Charts CANF vs CUEBanner chart's image
Can-Fite Biopharma
Price$4.29
Change-$0.00 (-0.00%)
Volume$3.7K
Capitalization3.67M
Cue Biopharma
Price$0.30
Change-$0.04 (-11.76%)
Volume$700
Capitalization31.11M
CANF vs CUE Comparison Chart in %
CANF
Daily Signal:
Gain/Loss:
CUE
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
CANF vs. CUE commentary
Jan 15, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CANF is a Hold and CUE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jan 15, 2026
Stock price -- (CANF: $4.29 vs. CUE: $0.34)
Brand notoriety: CANF and CUE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CANF: 8% vs. CUE: 93%
Market capitalization -- CANF: $3.67M vs. CUE: $31.11M
CANF [@Biotechnology] is valued at $3.67M. CUE’s [@Biotechnology] market capitalization is $31.11M. The market cap for tickers in the [@Biotechnology] industry ranges from $114.05B to $0. The average market capitalization across the [@Biotechnology] industry is $2.27B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CANF’s FA Score shows that 1 FA rating(s) are green whileCUE’s FA Score has 1 green FA rating(s).

  • CANF’s FA Score: 1 green, 4 red.
  • CUE’s FA Score: 1 green, 4 red.
According to our system of comparison, both CANF and CUE are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CANF’s TA Score shows that 6 TA indicator(s) are bullish while CUE’s TA Score has 5 bullish TA indicator(s).

  • CANF’s TA Score: 6 bullish, 2 bearish.
  • CUE’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, CANF is a better buy in the short-term than CUE.

Price Growth

CANF (@Biotechnology) experienced а -8.92% price change this week, while CUE (@Biotechnology) price change was -11.89% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.23%. For the same industry, the average monthly price growth was +2.54%, and the average quarterly price growth was +43.40%.

Reported Earning Dates

CUE is expected to report earnings on Mar 24, 2026.

Industries' Descriptions

@Biotechnology (-0.23% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CUE($31.1M) has a higher market cap than CANF($3.67M). CUE YTD gains are higher at: 11.657 vs. CANF (7.250). CANF has higher annual earnings (EBITDA): -8.91M vs. CUE (-35.19M). CUE has more cash in the bank: 18.7M vs. CANF (995K). CANF has less debt than CUE: CANF (90K) vs CUE (6.17M). CUE has higher revenues than CANF: CUE (7.1M) vs CANF (560K).
CANFCUECANF / CUE
Capitalization3.67M31.1M12%
EBITDA-8.91M-35.19M25%
Gain YTD7.25011.65762%
P/E RatioN/AN/A-
Revenue560K7.1M8%
Total Cash995K18.7M5%
Total Debt90K6.17M1%
FUNDAMENTALS RATINGS
CANF vs CUE: Fundamental Ratings
CANF
CUE
OUTLOOK RATING
1..100
3116
VALUATION
overvalued / fair valued / undervalued
1..100
11
Undervalued
22
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
9695
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CANF's Valuation (11) in the Biotechnology industry is in the same range as CUE (22). This means that CANF’s stock grew similarly to CUE’s over the last 12 months.

CANF's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as CUE (100). This means that CANF’s stock grew similarly to CUE’s over the last 12 months.

CANF's SMR Rating (100) in the Biotechnology industry is in the same range as CUE (100). This means that CANF’s stock grew similarly to CUE’s over the last 12 months.

CUE's Price Growth Rating (95) in the Biotechnology industry is in the same range as CANF (96). This means that CUE’s stock grew similarly to CANF’s over the last 12 months.

CUE's P/E Growth Rating (100) in the Biotechnology industry is in the same range as CANF (100). This means that CUE’s stock grew similarly to CANF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CANFCUE
RSI
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
82%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
69%
Bullish Trend 2 days ago
81%
MACD
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
79%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 14 days ago
76%
Bullish Trend 8 days ago
78%
Declines
ODDS (%)
Bearish Trend 7 days ago
88%
Bearish Trend 4 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
83%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
CANF
Daily Signal:
Gain/Loss:
CUE
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ADAG1.800.10
+5.88%
Adagene
CRVS6.820.32
+4.92%
Corvus Pharmaceuticals
STFS0.10N/A
+0.50%
Star Fashion Culture Holdings Ltd
GWRE170.85-8.65
-4.82%
Guidewire Software
DAVE185.46-26.26
-12.40%
Dave

CANF and

Correlation & Price change

A.I.dvisor indicates that over the last year, CANF has been loosely correlated with ALDX. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if CANF jumps, then ALDX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CANF
1D Price
Change %
CANF100%
+3.62%
ALDX - CANF
46%
Loosely correlated
+2.42%
NEVPF - CANF
30%
Poorly correlated
N/A
MREO - CANF
28%
Poorly correlated
+8.58%
TPST - CANF
27%
Poorly correlated
-6.59%
CUE - CANF
27%
Poorly correlated
-2.74%
More

CUE and

Correlation & Price change

A.I.dvisor indicates that over the last year, CUE has been loosely correlated with VCYT. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if CUE jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CUE
1D Price
Change %
CUE100%
-2.74%
VCYT - CUE
36%
Loosely correlated
-1.39%
AXON - CUE
33%
Loosely correlated
-1.92%
PYXS - CUE
32%
Poorly correlated
+5.85%
AMRN - CUE
32%
Poorly correlated
-0.99%
CRBU - CUE
32%
Poorly correlated
+1.26%
More